← Back to Search

Identification of specific markers for Low blood cell count

N/A

Waitlist Available

Research Sponsored by Meyer Children's Hospital IRCCS

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical and hematological diagnosis of autoimmune cytopenia

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every three to six months

Awards & highlights

Study Summary

This trial aims to better understand and find effective treatments for autoimmune cytopenias, which are common in patients with immune system disorders. Current treatments often fail, leading to high costs and health risks. The

Who is the study for?

This trial is for patients with autoimmune cytopenias, which include conditions like low platelet count, anemia, and low white blood cell count that are resistant to treatment. These patients may also have primary immunodeficiencies (PI).Check my eligibility

What is being tested?

The study aims to identify specific early biomarkers in the immune system that can help diagnose autoimmune cytopenias and predict who will respond well to therapy.See study design

What are the potential side effects?

Since this trial focuses on identification of biomarkers rather than testing a drug or medical intervention, there are no direct side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a blood disorder where my immune system attacks my blood cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every three to six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every three to six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and every three to six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Identification of specific markers

Trial Design

1Treatment groups

Experimental Treatment

Group I: Identification of specific markersExperimental Treatment1 Intervention

Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Meyer Children's Hospital IRCCSLead Sponsor

39 Previous Clinical Trials

12,840 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For which individuals is participation in this research study deemed appropriate?

"To be eligible for enrollment in this study, individuals must exhibit cytopenia and fall between the ages of 12 months and 17 years. The trial is currently open to approximately 53 participants."

Answered by AI

Is the research study open to participants who have reached the age of thirty?

"Participants in this research must be aged between 12 months and 17 years. Among the studies listed, there are 133 trials focusing on individuals under 18 years old and 273 targeted towards those above 65 years of age."

Answered by AI

At how many distinct sites is the management of this study taking place?

"Enrollment for this research is ongoing at several prestigious institutions such as IRCCS Istituto Giannina Gaslini in Genova, University of South Florida in Tampa, and Clinica Pediatrica - Università di Catania in Catania. Additionally, there are recruitment efforts underway at 6 other sites."

Answered by AI

Are there any available slots for patients to participate in this research study?

"As per the information available on clinicaltrials.gov, recruitment for this particular trial is currently inactive. The trial was first listed on 23rd July 2019 and last modified on 18th February 2024. Despite its current dormant status, there are a total of 369 other active trials seeking participants presently."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Eleonora Gambineri 2019. "Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06276036.

All > Thrombocytopenia